The study and its comparison
Fifty-nine adults with longstanding moderate-to-severe depression were randomized to psilocybin sessions with daily placebo or escitalopram with very-low-dose psilocybin sessions. Both groups received psychological support. [1]
The primary self-reported depression-score change did not significantly differ at six weeks. Several secondary outcomes favored psilocybin, but those analyses lacked correction for multiple comparisons. [1]
What the finding establishes
A nonsignificant difference does not prove equivalence, and secondary findings do not replace the primary result. The small, short trial cannot rank treatments for every patient. Funding came from the Alexander Mosley Charitable Trust and Imperial’s research center; full conflicts were not established from the abstract. Do not alter prescribed treatment based on this comparison alone. [1]
A hypothetical distinction
Imagine many secondary tests are reported. Their apparent positives require attention to multiplicity.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Trial of Psilocybin versus Escitalopram for Depression.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.